Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. ACADIA Pharmaceuticals Inc.
  6. Summary
    ACAD   US0042251084

ACADIA PHARMACEUTICALS INC.

(ACAD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/08/2021 06/09/2021 06/10/2021 06/11/2021 06/14/2021 Date
26.57(c) 26.13(c) 27.3(c) 27.42(c) 27.24(c) Last
1 986 047 1 787 321 1 694 301 1 201 621 1 442 673 Volume
+4.61% -1.66% +4.48% +0.44% -0.66% Change
More quotes
Financials (USD)
Sales 2021 523 M - -
Net income 2021 -197 M - -
Net cash position 2021 447 M - -
P/E ratio 2021 -22,4x
Yield 2021 -
Sales 2022 648 M - -
Net income 2022 -121 M - -
Net cash position 2022 452 M - -
P/E ratio 2022 -37,2x
Yield 2022 -
Capitalization 4 363 M 4 363 M -
EV / Sales 2021 7,49x
EV / Sales 2022 6,04x
Nbr of Employees 640
Free-Float 98,7%
More Financials
Company
ACADIA Pharmaceuticals Inc. (ACADIA) is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines to address the medical needs in central nervous system disorders. The Company's lead product, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA’s developments are focused on... 
Read more
More about the company
Ratings of ACADIA Pharmaceuticals Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about ACADIA PHARMACEUTICALS INC.
06/11DEADLINE ALERT : Bragar Eagel & Squire, P.C. Reminds Investors That a Class Acti..
BU
06/11ACAD BREAKING ALERT : ROSEN, A LONGSTANDING LAW FIRM, Encourages Acadia Pharmace..
BU
06/11SHAREHOLDER ALERT : Pomerantz Law Firm Reminds Shareholders with Losses on their..
PR
06/10ACADIA PHARMACEUTICALS  : Berenberg Bank Initiates Coverage on ACADIA Pharmaceut..
MT
06/04ACADIA PHARMACEUTICALS  : NUPLAZID (pimavanserin) Efficacy Data from Open-Label ..
AQ
06/03ACADIA PHARMACEUTICALS  : NUPLAZID® (pimavanserin) Efficacy Data from Open-Label..
BU
06/01SHAREHOLDER ALERT : Pomerantz Law Firm Reminds Shareholders with Losses on their..
PR
05/28ACADIA PHARMACEUTICALS  : ROSEN, SKILLED INVESTOR COUNSEL, Encourages Acadia Pha..
PR
05/28ACADIA PHARMACEUTICALS  : The Law Offices of Frank R. Cruz Announces the Filing ..
PR
05/26ACADIA PHARMACEUTICALS  : to Present at Upcoming Investor Conferences
BU
05/25SHAREHOLDER ALERT : Pomerantz Law Firm Reminds Shareholders with Losses on their..
PR
05/24DEADLINE REMINDER : Law Offices of Howard G. Smith Reminds Investors of Looming ..
PR
05/18SHAREHOLDER ALERT : Pomerantz Law Firm Reminds Shareholders with Losses on their..
PR
05/13GLANCY PRONGAY & MURRAY LLP  : Reminds Investors of Looming Deadline in the Clas..
PR
05/13SHAREHOLDER ALERT : Pomerantz Law Firm Reminds Shareholders with Losses on their..
PR
More news
News in other languages on ACADIA PHARMACEUTICALS INC.
06/11WALL STREET STOCK EXCHANGE : USA-Les valeurs à suivre à Wall Street (actualisé)
03/12BOOST / FAIL  : les tops & flops de la semaine ! #2
03/10WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
2016ACADIA PHARMACEUTICALS  : le Nuplazid bientôt disponible aux Etats-Unis
2016Les valeurs à suivre sur les marchés américains
More news
Analyst Recommendations on ACADIA PHARMACEUTICALS INC.
More recommendations
Analysis
Canada's RBC turns heads in U.S. with wealth management recruitment push
Chart ACADIA PHARMACEUTICALS INC.
Duration : Period :
ACADIA Pharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACADIA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 27,58 $
Last Close Price 27,24 $
Spread / Highest target 54,2%
Spread / Average Target 1,24%
Spread / Lowest Target -33,9%
EPS Revisions
Managers and Directors
NameTitle
Stephen R. Davis Chief Executive Officer & Director
Srdjan R. Stankovic President
Elena H. Ridloff Chief Financial Officer & Executive Vice President
Stephen R. Biggar Chairman
Bob Mischler Senior VP-Strategy & Technology Operations
Sector and Competitors
1st jan.Capitalization (M$)
ACADIA PHARMACEUTICALS INC.-49.05%4 363
MODERNA, INC.98.54%87 874
LONZA GROUP AG16.32%54 656
IQVIA HOLDINGS INC.36.45%46 658
CELLTRION, INC.-21.73%32 458
SEAGEN INC.-10.76%28 416